Al-Modawat H1 2024 net profit declines 71% to 3.2M

01/09/2024 Argaam Exclusive

Al-Modawat Specialized Medical Co.’s net profit declined 71% to SAR 3.2 million in the first half of 2024, compared to SAR 10.9 million in the prior-year period.



Current Half Annual Comparison (Million Riyal)

Compared With The
Item H1 2023 H1 2024 Change‬
Revenues 37.18 37.29 0.3 %
Gross Income 21.40 17.33 (19.0 %)
Operating Income 11.52 3.79 (67.1 %)
Net Income 10.93 3.16 (71.1 %)
Average Shares 57.00 71.25 25.0 %
Earnings Per Share before unusual items (Riyal) 0.19 0.04 (76.9 %)
EPS (Riyal) 0.19 0.04 (76.9 %)

The drop was attributed to the additional expenses for listing on Nomu-Parallel Market and the higher costs dedicated for leveraging the medical services efficiency.

 

This was offset by an increase in sales and revenues during the first half of 2024 compared to the same period last year, a continued growth in all operational segments, and the increase in the number of hospital rooms.

 

Shareholders’ equity, no minority interest, rose to SAR 78.51 million as of June 30, 2024, from SAR 37.12 million a year earlier.

 

Historical Data 

Period  

Revenue 

(SAR mln)  

Net Profit 

(SAR mln)   

EPS 

(SAR/Share)  

H1 2022

25.30

3.64

0.19

H2 2022

33.27

6.67

0.35

H1 2023

37.18

10.93

0.58

H2 2023

37.13

7.66

0.40

H1 2024

37.29

3.16

0.13

H1 2024

33.27

6.67

0.35

 

View More Financial Results

 

View other reports

Share Price

Al-Modawat Specialized Medical Co.
5.50
0.09 1.66 %

Al-Modawat Specialized Medical Co. (ALMODAWAT)

More


Financial Ratios
Current
Market Cap (M Riyal) 391.88
Enterprise Value (EV) (M Riyal) 406.36
Shares Outstanding ((M)) 71.25
Recurring EPS ( Riyal) (TTM) 0.27
Book Value (BV) ( Riyal) 1.24
Par Value ( Riyal) 1.00
Recurring P/E 20.65
P/E (TTM) 20.65
Price/book 4.44
Return on Average Assets (%) (TTM) 13.6
Return on Average Equity (%) (TTM) 22.9
EV/adj EBITDA 13.42
EV/Revenues 3.34
more


Financial results (Million Riyal)

Period Revenues Change Gross Income Change Operating Income Change
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 25.30 - 11.91 - 4.05 -
H2 2022 33.26 - 16.61 - 7.40 -
H1 2023 37.18 46.9 % 21.40 79.8 % 11.52 184.6 %
H2 2023 37.13 11.6 % 19.23 15.8 % 8.65 17.0 %
H1 2024 37.29 0.3 % 17.33 (19.0 %) 3.79 (67.1 %)


Profit Performance (Million Riyal)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS(Riyal)
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 3.64 - 0.06 - 3.64 0.06
H2 2022 6.67 - 0.12 - 6.67 0.12
H1 2023 10.93 200.4 % 0.19 - 10.93 0.19
H2 2023 7.66 14.8 % 0.13 - 7.66 0.13
H1 2024 3.16 (71.1 %) 0.04 - 3.16 0.04

Profitability

Period Gross Margin Adjusted EBITDA margin Net Margin Before Unusual Items
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 48.69 % 22.19 % 17.61 %
H1 2023 53.96 % 30.58 % 25.00 %
H2 2023 54.67 % 32.07 % 25.02 %
2023 54.68 % 32.07 % 25.02 %
H1 2024 49.12 % 22.40 % 14.54 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Earnings Per Share before unusual items (Riyal) Book Value (BV)
H1 2020 - - - -
H2 2020 - - - -
H1 2021 - - - -
H2 2021 - - - -
H1 2022 57.00 - - 0.40
H2 2022 57.00 0.18 0.18 0.54
H1 2023 57.00 0.31 0.31 0.65
H2 2023 57.00 0.33 0.33 0.69
H1 2024 71.25 0.15 0.15 1.10

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Recurring P/E Price/book
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 - - -
H1 2023 - - -
H2 2023 - - -
H1 2024 33.35 33.35 4.60

Business Segments (Million Riyal)

Compared With The
Period Medical Services Pharmaceutical Products Other
H1 2022 23.69 1.61 -
H2 2022 31.82 1.44 -
H1 2023 35.50 1.67 -
H2 2023 35.40 1.73 -
H1 2024 35.27 2.01 -

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2026, Argaam Investment, All Rights Reserved
Call Request